<DOC>
	<DOCNO>NCT00184951</DOCNO>
	<brief_summary>open-label , multiple dose , single-group , 12 week trial HIV-infected patient hyperlipidemia use lopinavir/ritonavir ; male female subject .</brief_summary>
	<brief_title>Pharmacokinetic Study Rosuvastatin Lopinavir/Ritonavir HIV Patients</brief_title>
	<detailed_description>To determine effect rosuvastatin plasma lipid , lipoprotein , endothelial function HIV-infected patient stable lopinavir/ritonavir therapy evaluate safety combine use rosuvastatin lopinavir/ritonavir . Also determine effect lopinavir/ritonavir pharmacokinetics rosuvastatin compare historical control determine effect rosuvastatin pk lopinavir/ritonavir compare historical control intrapatient comparison .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>use lopinavir 400mg/ritonavir 100mg bid &gt; 3months HIV1 RNA &lt; 400cop/mL fast total cholesterol &gt; 6.2mmol/L history sensitivity/idiosyncrasy drug compound use history current condition might interfere absorption , distribution metabolism excretion pregnant breastfeeding serum transaminase level &gt; 3 time upper limit normal , creatinine clearance &lt; 60ml/min fast plasma triglyceride level &gt; 8.0 mmol/L history statinrelated rhabdomyolysis inheritable muscle disease family history clinical symptom myopathy abnormal CK level change antiretroviral medication within 3 month immediately precede first dose rosuvastatin use statin fibrate within 6 week immediately precede first dose rosuvastatin concomitant use medication interfere rosuvastatin lopinavir pharmacokinetics active hepatobiliary hepatic disease hypothyroidism alcohol abuse japanese chinese patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>HIV</keyword>
</DOC>